


## GNE-502

## Chemical Properties

CAS No. :	1953134-16-1
Formula:	C <sub>25</sub> H <sub>30</sub> FN <sub>3</sub> O <sub>3</sub> S
Molecular Weight:	471.59
Storage:	Powder: -20°C for 3 years   In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



## Biological Description

Description	GNE-502, an orally active and potent estrogen receptor (ER) degrader, is specifically designed for breast cancer research.
Targets(IC50)	Estrogen Receptor/ERR,Others
In vivo	GNE-502, administered orally at doses of 10 and 100 mg/kg, demonstrates adequate oral bioavailability for evaluation in a WT MCF7 tumor xenograft mouse model. It exhibits dose-dependent tumor growth inhibition at 10 and 30 mg/kg and achieves tumor stasis at 100 mg/kg, indicative of its potential efficacy in cancer therapy. Dosage and administration details for pharmacokinetic analysis confirm its sufficient oral exposure for effectiveness in the specified model.

## Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.1205 mL	10.6024 mL	21.2049 mL
5 mM	0.4241 mL	2.1205 mL	4.241 mL
10 mM	0.212 mL	1.0602 mL	2.1205 mL
50 mM	0.0424 mL	0.212 mL	0.4241 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

## Reference

Zbieg JR, et al. Discovery of GNE-502 as an Orally Bioavailable and Potent Degradar for Estrogen Receptor Positive Breast Cancer [published online ahead of print, 2021 Aug 20]. *Bioorg Med Chem Lett.* 2021;128335.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481